Fatty acid synthase (FAS) a racts more and more attention recently as a potential target for
metabolic syndrome, such as cancer, obesity, diabetes and cerebrovascular disease. FAS …

Recently, animal fatty acid synthase (FAS) is reported as a potential therapeutic target for
obesity and cancer. Considerable interest has been developed in identifying novel inhibitors …

Purpose: Fatty acid synthase (FASN) is overexpressed in human breast carcinoma. The
natural polyphenol (−)-epigallocatechin-3-gallate blocks in vitro FASN activity and leads to …

Fatty acid synthase (FAS) is a potential target for cancer, but potent inhibitors against FAS
are scarce. In this study, we found that activities of catechins on inhibiting FAS increased …

Fatty acid synthase (FASN) is a multifunctional enzyme involved in the production of fatty
acids for lipid biosynthesis. FASN is overexpressed in multiple diseases like cancer, viral …

Assignee Company: Janssen Pharmaceutica NV; Turnhoutseweg 30, B-2340 Beerse (BE)
Disease Area: Cancer, obesity related disorders, and liver related disorders Biological …

Fatty acid synthase (FASN) is a lipogenic enzyme that is highly expressed in different human
cancers. Here we report the development of a new series of polyphenolic compounds 5–30 …

Fatty acid synthase (EC 2. 3. 1. 85, abbr. FAS) is reported as a potential new therapeutic
target for the treatment of obesity. Thirty one Chinese medicinal herbs used in weight …

Fatty acid synthase (FASN), an enzyme capable of de novo fatty acid synthesis, is highly
expressed and activated in most human carcinomas. FASN is associated with poor …

Fatty acid synthase (FASN) is a key enzyme involved in neoplastic lipogenesis.
Overexpression of FASN is common in many cancers, and accumulating evidence suggests …